A Phase 2 interventional study of MSTT1041A and MSTT1041A-matched Placebo in COVID-19 Pneumonia, sponsored by Genentech, Inc.. Completed at 41 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-10.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 345th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 317th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 396 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
Hoffmann-La Roche has 9 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase II, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of MSTT1041A (astegolimab) compared with placebo and of UTTR1147A compared with placebo, in combination with standard of care (SOC), in patients hospitalized with severe coronavirus disease 2019 (COVID-19) pneumonia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm received one intravenous (IV) infusion of either MSTT1041A-matched placebo or UTTR1147A-matched placebo on Day 1. A second IV infusion of either MSTT1041A-matched placebo or UTTR1147A-matched placebo (same placebo as the first infusion) was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
Drug: MSTT1041A-matched Placebo · Drug: UTTR1147A-matched Placebo
Participants randomized to this arm received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
Drug: MSTT1041A
Participants randomized to this arm received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
Drug: UTTR1147A
Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
Also known as: Astegolimab, RG6149, RO7187807
Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.
Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
Also known as: Efmarodocokin alfa, RG7880, RO7021610, IL-22Fc
Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.
Time to Recovery, Defined as the Time to a Clinical Status Score of 1 or 2 on the 7-Category Ordinal Scale (Whichever Occurs First) by Day 28
The time to recovery was defined as the time from baseline to a clinical status score of 1 or 2 on the 7-category ordinal scale (whichever occurs first); clinical status scores are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death.
Time frame: From Baseline up to 28 days
Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status by Day 28
The 7 categories of the clinical status ordinal scale are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring ECMO or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death
Time frame: From Baseline up to 28 days
Time to Hospital Discharge or "Ready for Discharge" by Day 28
Hospital discharge is category number 1 out of the 7 categories of the clinical status ordinal scale, and it is defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen).
Time frame: Up to 28 days
Duration of Supplemental Oxygen by Day 28
Duration of supplemental oxygen was defined as the number of days during the 28-day treatment period when the participant is alive and receives "Supplemental Oxygen or other forms of ventilation", as recorded in the Vital Signs and Oxygen Saturation form. For each participant, the duration of multiple non-consecutive periods during which the participant received supplemental oxygen was summed. For any days prior to Day 28 where status of supplemental oxygen use was missing, the last known status was to be carried forward.
Time frame: Up to 28 days
Percentage of Participants Alive and Free of Respiratory Failure by Day 28
Respiratory failure was defined as requiring non-invasive ventilation, high-flow oxygen, mechanical ventilation, or extracorporeal membrane oxygenation \[ECMO\]).
Time frame: Up to 28 days
Clinical Status Score at Day 14, Assessed Using a 7-Category Ordinal Scale
The clinical status scores of the 7 category ordinal scale are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring ECMO or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death
Time frame: Day 14
Clinical Status Score at Day 28, Assessed Using a 7-Category Ordinal Scale
The clinical status scores of the 7 category ordinal scale are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring ECMO or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death
Time frame: Day 28
Percentage of Participants Needing Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Day 28
Time frame: Up to 28 days
Number of Ventilator-Free Days by Day 28
The number of ventilator-free days was defined as the number of days during the 28-day treatment period when the participant is alive and without need for invasive mechanical ventilation. For any day during Day 1 and Day 28, if invasive mechanical ventilation or ECMO was recorded for any part of the day ( \>= 12 hours during mechanical invasive ventilation for patients with tracheostomy), the day was not to be counted as a ventilator-free day; otherwise, the day was to be counted. For any days prior to Day 28 where status of mechanical ventilator was missing, the last known status was to be carried forward. The total number of days was the sum of all ventilator-free days, regardless of whether the days occurred consecutively or in nonconsecutive intervals.
Time frame: Up to 28 days
Percentage of Participants With an Intensive Care Unit (ICU) Stay by Day 28
Time frame: Up to 28 days
Duration of Intensive Care Unit (ICU) Stay by Day 28
Duration of ICU stay was calculated as the total number of hours (expressed in days) spent in ICU up to and inclusive of 28 days. ICU duration was derived from the ICU Stay Information Log using the difference between ICU discharge date/time and ICU admission date/time. If ICU admission occurred before randomization, the ICU duration was to be counted from the date of dosing. Partial admission and discharge date/time were to be imputed following a conservative approach. For each participant, durations of multiple ICU stays were to be summed.
Time frame: Up to 28 days
Time to Clinical Failure by Day 28, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal of Care (Whichever Occurs First)
Time frame: Up to 28 days
Percentage of Participants Who Died by Day 14
Time frame: Up to Day 14
Percentage of Participants Who Died by Day 28
Time frame: Up to Day 28
Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) Aggregate Score of ≤2 Maintained for 24 Hours
The National Early Warning Score 2 (NEWS2) is a system for scoring the physiological measurements that are routinely recorded at the patient's bedside. Its purpose is to identify acutely ill patients. The NEWS2 scoring system measures 7 physiological parameters: respiration rate, peripheral capillary oxygen saturation, breathing air or supplementary oxygen, systolic blood pressure, pulse rate, level of consciousness or new-onset confusion, and body temperature. A score of 0, 1, 2, or 3 is allocated to each parameter (except for air or oxygen, with respective scores of 0 and 2); a higher score means the parameter is further from the normal range. The scores for each parameter are then summed (with an aggregate score ranging from 0 to 20), and a higher aggregate score indicates a worse clinical condition of the patient, thus indicating the need for a more urgent clinical response.
Time frame: Up to 28 days
Safety Summary of the Number of Participants With at Least One Adverse Event, With Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
The terms "severe" and "serious" are not synonymous with respect to an adverse event (AE). Severity refers to the intensity of an AE (rated according to NCI-CTCAE v5.0 criteria or, if not listed, the following scale: Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to AE), whereas a serious AE (SAE) is a significant medical event (per standard SAE criteria), such as a life-threatening or fatal AE or an AE that prolongs inpatient hospitalization. Severity and seriousness were independently assessed by the investigator for each AE that was recorded. The investigator also assessed each AE for whether the event was considered to be related to the study drug.
Time frame: From Baseline until study completion/discontinuation (up to 60 days)
Number of Participants With Clinical Laboratory Test Abnormalities by Highest NCI-CTCAE Grade Post-Baseline
Clinical laboratory tests were performed over the course of the study and the grading of any abnormal values outside of the normal range (High or Low) was based on the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0); the higher the grade, the greater the lab parameter deviated from the normal range. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. SGPT/ALT = alanine aminotransferase; SGOT/AST = aspartate aminotransferase; INR = international normalized ratio; aPTT = activated partial thromboplastin time
Time frame: From Baseline up to 60 days
Number of Participants With Vital Sign Abnormalities at Anytime Post-Baseline
The number of participants with vital sign abnormalities outside of the normal upper (i.e., High) and lower limits (i.e., Low) were summarized for each parameter. The normal reference range used for each vital sign parameter was as follows: Diastolic Blood Pressure, 50-90 millimetres of mercury (mmHg); Oxygen Saturation, ≥94%; Pulse Rate, 60-100 beats per minute; Respiratory Rate, 8-20 breaths per minute; Systolic Blood Pressure, 90-140 mmHg; Temperature, 36.5-38 degrees Celsius (C). Not every vital sign abnormality qualified as an adverse event. A vital sign result was to be reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgement.
Time frame: From Baseline up to 60 days
Number of Participants by the Investigator's Interpretations of Electrocardiogram Recordings at Specified Timepoints
Electrocardiogram (ECG) recordings were to be performed after the participant had been resting in a supine position for at least 10 minutes if possible. The investigator's interpretation of the ECG (e.g., normal or abnormal) was recorded.
Time frame: Baseline, Days 14 and 28, Discharge Day (up to Day 28), and Study Completion Visit (up to Day 60)
Percentage of Participants Who Tested Positive for Anti-Drug Antibodies (ADAs) to MSTT1041A and UTTR1147A at Baseline and at Anytime Post-Baseline
Serum samples were collected, and participants who received treatment with MSTT1041A or MSTT1041A-matched placebo were assessed for antidrug antibodies (ADAs) to MSTT1041A, while those who received UTTR1147A or UTTR1147A-matched placebo were assessed for ADAs to UTTR1147A. Participants who received placebo treatment were only assessed for the presence of ADAs at baseline. The percentage of ADA-positive participants at baseline (baseline prevalence) and after drug administration (postbaseline incidence) are summarized. When determining postbaseline incidence, participants were considered to be ADA positive if they were ADA negative or had missing data at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more postbaseline samples was at least 0.60 titer unit greater than the titer of the baseline sample (treatment-enhanced ADA response).
Time frame: At Baseline (pre-dose on Day 1) and post-baseline (Days 15 and 28; and discharge day and study completion [up to 60 days])
Serum Concentration of UTTR1147A at Specified Timepoints
Time frame: For the first dose: at 0.5 hours post-dose on Day 1, on Days 2, 3, 7, and 15; and for the second dose: Days 15 (0.5 hours post-dose), 21, and 28
Serum Concentration of MSTT1041A at Specified Timepoints
Time frame: For the first dose: at 0.5 hours post-dose on Day 1, on Days 2, 3, 7, and 15; and for the second dose: Days 15 (0.5 hours post-dose), 21, and 28
| Milestone | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Started | 134 | 130 | 132 |
| Received at least one dose of study drug | 134 | 130 | 132 |
| Completed both doses of study drug at day 15 | 31 | 27 | 25 |
| Completed | 104 | 95 | 104 |
| Not completed | 30 | 35 | 28 |
| Withdrew: Death | 22 | 22 | 21 |
| Withdrew: Lost to follow-up | 5 | 8 | 6 |
| Withdrew: Withdrawal by subject | 2 | 4 | 1 |
| Withdrew: Adverse event | 1 | 1 | 0 |
The time to recovery was defined as the time from baseline to a clinical status score of 1 or 2 on the 7-category ordinal scale (whichever occurs first); clinical status scores are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death.
| Days | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Time to Recovery, Defined as the Time to a Clinical Status Score of 1 or 2 on the 7-Category Ordinal Scale (Whichever Occurs First) by Day 28 | 10.0 (8.0 to 14.0) | 11.0 (9.0 to 14.0) | 10.0 (8.0 to 13.0) |
The 7 categories of the clinical status ordinal scale are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring ECMO or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death
| Days | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status by Day 28 | 10.0 (8.0 to 14.0) | 11.0 (9.0 to 13.0) | 10.0 (8.0 to 12.0) |
Hospital discharge is category number 1 out of the 7 categories of the clinical status ordinal scale, and it is defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen).
| Days | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Time to Hospital Discharge or "Ready for Discharge" by Day 28 | 10.0 (8.0 to 14.0) | 11.0 (9.0 to 13.0) | 10.0 (8.0 to 13.0) |
Duration of supplemental oxygen was defined as the number of days during the 28-day treatment period when the participant is alive and receives "Supplemental Oxygen or other forms of ventilation", as recorded in the Vital Signs and Oxygen Saturation form. For each participant, the duration of multiple non-consecutive periods during which the participant received supplemental oxygen was summed. For any days prior to Day 28 where status of supplemental oxygen use was missing, the last known status was to be carried forward.
| Days | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Duration of Supplemental Oxygen by Day 28 | 18.00 (13.00 to 27.00) | 17.00 (11.00 to 27.00) | 13.50 (10.00 to 21.00) |
Respiratory failure was defined as requiring non-invasive ventilation, high-flow oxygen, mechanical ventilation, or extracorporeal membrane oxygenation \[ECMO\]).
| Percentage of participants | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Percentage of Participants Alive and Free of Respiratory Failure by Day 28 | 38.1 (29.47 to 46.65) | 39.2 (30.45 to 48.01) | 40.2 (31.41 to 48.89) |
The clinical status scores of the 7 category ordinal scale are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring ECMO or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death
| Score on a scale | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Clinical Status Score at Day 14, Assessed Using a 7-Category Ordinal Scale | 1.0 (1.0 to 4.0) | 1.0 (1.0 to 3.0) | 1.0 (1.0 to 4.0) |
The clinical status scores of the 7 category ordinal scale are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring ECMO or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death
| Score on a scale | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Clinical Status Score at Day 28, Assessed Using a 7-Category Ordinal Scale | 1.0 (1.0 to 4.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| Percentage of participants | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Percentage of Participants Needing Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Day 28 | 24.6 (16.96 to 32.29) | 28.5 (20.32 to 36.60) | 24.2 (16.55 to 31.93) |
The number of ventilator-free days was defined as the number of days during the 28-day treatment period when the participant is alive and without need for invasive mechanical ventilation. For any day during Day 1 and Day 28, if invasive mechanical ventilation or ECMO was recorded for any part of the day ( \>= 12 hours during mechanical invasive ventilation for patients with tracheostomy), the day was not to be counted as a ventilator-free day; otherwise, the day was to be counted. For any days prior to Day 28 where status of mechanical ventilator was missing, the last known status was to be carried forward. The total number of days was the sum of all ventilator-free days, regardless of whether the days occurred consecutively or in nonconsecutive intervals.
| Days | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Number of Ventilator-Free Days by Day 28 | 28.0 (20.00 to 28.00) | 28.0 (20.00 to 28.00) | 28.0 (23.50 to 28.00) |
| Percentage of participants | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Percentage of Participants With an Intensive Care Unit (ICU) Stay by Day 28 | 58.2 (49.48 to 66.93) | 54.6 (45.67 to 63.56) | 46.2 (37.33 to 55.10) |
Duration of ICU stay was calculated as the total number of hours (expressed in days) spent in ICU up to and inclusive of 28 days. ICU duration was derived from the ICU Stay Information Log using the difference between ICU discharge date/time and ICU admission date/time. If ICU admission occurred before randomization, the ICU duration was to be counted from the date of dosing. Partial admission and discharge date/time were to be imputed following a conservative approach. For each participant, durations of multiple ICU stays were to be summed.
| Days | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Duration of Intensive Care Unit (ICU) Stay by Day 28 | 3.10 (0.00 to 5.23) | 2.62 (0.00 to 6.02) | 0.00 (0.00 to 2.14) |
| Days | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Time to Clinical Failure by Day 28, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal of Care (Whichever Occurs First) | NA (13.0 to NA) | NA (9.0 to NA) | NA (NA to NA) |
| Percentage of participants | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Percentage of Participants Who Died by Day 14 | 6.0 (1.59 to 10.35) | 8.5 (3.29 to 13.63) | 8.3 (3.24 to 13.43) |
| Percentage of participants | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Percentage of Participants Who Died by Day 28 | 11.2 (5.48 to 16.91) | 14.6 (8.16 to 21.07) | 12.9 (6.79 to 18.97) |
The National Early Warning Score 2 (NEWS2) is a system for scoring the physiological measurements that are routinely recorded at the patient's bedside. Its purpose is to identify acutely ill patients. The NEWS2 scoring system measures 7 physiological parameters: respiration rate, peripheral capillary oxygen saturation, breathing air or supplementary oxygen, systolic blood pressure, pulse rate, level of consciousness or new-onset confusion, and body temperature. A score of 0, 1, 2, or 3 is allocated to each parameter (except for air or oxygen, with respective scores of 0 and 2); a higher score means the parameter is further from the normal range. The scores for each parameter are then summed (with an aggregate score ranging from 0 to 20), and a higher aggregate score indicates a worse clinical condition of the patient, thus indicating the need for a more urgent clinical response.
| Days | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) Aggregate Score of ≤2 Maintained for 24 Hours | 5.5 (4.0 to 7.0) | 6.0 (4.0 to 8.0) | 6.0 (3.0 to 9.0) |
The terms "severe" and "serious" are not synonymous with respect to an adverse event (AE). Severity refers to the intensity of an AE (rated according to NCI-CTCAE v5.0 criteria or, if not listed, the following scale: Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to AE), whereas a serious AE (SAE) is a significant medical event (per standard SAE criteria), such as a life-threatening or fatal AE or an AE that prolongs inpatient hospitalization. Severity and seriousness were independently assessed by the investigator for each AE that was recorded. The investigator also assessed each AE for whether the event was considered to be related to the study drug.
| Participants | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Any Adverse Event (AE) | 87 | 85 | 95 |
| AE with Fatal Outcome | 23 | 23 | 21 |
| Serious AE (SAE) | 38 | 38 | 34 |
| SAE Leading to Withdrawal from Treatment | 2 | 2 | 1 |
| SAE Leading to Dose Modification/Interruption | 0 | 0 | 0 |
| Related SAE | 0 | 2 | 3 |
| AE Leading to Withdrawal from Treatment | 4 | 3 | 3 |
| AE Leading to Dose Modification/Interruption | 0 | 0 | 0 |
| Related AE | 15 | 12 | 25 |
| Related AE Leading to Withdrawal from Treatment | 0 | 0 | 1 |
| Related AE Leading to Dose Modification/Interruption | 0 | 0 | 0 |
| Grade 3-5 AE | 43 | 46 | 41 |
Clinical laboratory tests were performed over the course of the study and the grading of any abnormal values outside of the normal range (High or Low) was based on the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0); the higher the grade, the greater the lab parameter deviated from the normal range. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. SGPT/ALT = alanine aminotransferase; SGOT/AST = aspartate aminotransferase; INR = international normalized ratio; aPTT = activated partial thromboplastin time
| Participants | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Albumin, Low - Any Grade | 103 | 105 | 118 |
| Albumin, Low - Grade 1 | 32 | 36 | 40 |
| Albumin, Low - Grade 2 | 56 | 58 | 66 |
| Albumin, Low - Grade 3 | 15 | 11 | 12 |
| Alkaline Phosphatase, High - Any Grade | 20 | 23 | 24 |
| Alkaline Phosphatase, High - Grade 1 | 14 | 22 | 22 |
| Alkaline Phosphatase, High - Grade 2 | 5 | 1 | 1 |
| Alkaline Phosphatase, High - Grade 3 | 1 | 0 | 1 |
| SGPT/ALT, High - Any Grade | 60 | 48 | 60 |
| SGPT/ALT, High - Grade 1 | 48 | 37 | 47 |
| SGPT/ALT, High - Grade 2 | 5 | 7 | 7 |
| SGPT/ALT, High - Grade 3 | 5 | 3 | 5 |
| SGPT/ALT, High - Grade 4 | 2 | 1 | 1 |
| SGOT/AST, High - Any Grade | 47 | 38 | 44 |
| SGOT/AST, High - Grade 1 | 40 | 30 | 36 |
| SGOT/AST, High - Grade 2 | 4 | 5 | 4 |
| SGOT/AST, High - Grade 3 | 0 | 2 | 2 |
| SGOT/AST, High - Grade 4 | 3 | 1 | 2 |
| Calcium, Low - Any Grade | 73 | 82 | 84 |
| Calcium, Low - Grade 1 | 34 | 47 | 48 |
| Calcium, Low - Grade 2 | 31 | 26 | 29 |
| Calcium, Low - Grade 3 | 5 | 7 | 4 |
| Calcium, Low - Grade 4 | 3 | 2 | 3 |
| Calcium, High - Any Grade | 5 | 2 | 4 |
| Calcium, High - Grade 1 | 5 | 2 | 4 |
| Creatinine, High - Any Grade | 24 | 39 | 29 |
| Creatinine, High - Grade 1 | 6 | 11 | 8 |
| Creatinine, High - Grade 2 | 11 | 24 | 15 |
| Creatinine, High - Grade 3 | 7 | 3 | 5 |
| Creatinine, High - Grade 4 | 0 | 1 | 1 |
| Fibrinogen, Low - Any Grade | 7 | 3 | 1 |
| Fibrinogen, Low - Grade 1 | 1 | 1 | 0 |
| Fibrinogen, Low - Grade 2 | 3 | 2 | 0 |
| Fibrinogen, Low - Grade 3 | 2 | 0 | 0 |
| Fibrinogen, Low - Grade 4 | 1 | 0 | 1 |
| Glucose, Low - Any Grade | 8 | 11 | 12 |
| Glucose, Low - Grade 1 | 6 | 6 | 9 |
| Glucose, Low - Grade 2 | 1 | 5 | 0 |
| Glucose, Low - Grade 3 | 1 | 0 | 2 |
| Glucose, Low - Grade 4 | 0 | 0 | 1 |
| Hemoglobin, Low - Any Grade | 77 | 72 | 78 |
| Hemoglobin, Low - Grade 1 | 43 | 47 | 46 |
| Hemoglobin, Low - Grade 2 | 17 | 17 | 21 |
| Hemoglobin, Low - Grade 3 | 17 | 8 | 11 |
| Hemoglobin, High - Any Grade | 9 | 7 | 5 |
| Hemoglobin, High - Grade 1 | 9 | 6 | 5 |
| Hemoglobin, High - Grade 3 | 0 | 1 | 0 |
| Lymphocytes, Absolute Count (Abs), Low - Any Grade | 61 | 45 | 48 |
| Lymphocytes, Abs, Low - Grade 1 | 14 | 9 | 11 |
| Lymphocytes, Abs, Low - Grade 2 | 23 | 17 | 23 |
| Lymphocytes, Abs, Low - Grade 3 | 23 | 18 | 11 |
| Lymphocytes, Abs, Low - Grade 4 | 1 | 1 | 3 |
| Lymphocytes, Abs, High - Any Grade | 4 | 4 | 1 |
| Lymphocytes, Abs, High - Grade 2 | 4 | 4 | 1 |
| Neutrophils, Total (Abs), Low - Any Grade | 5 | 3 | 1 |
| Neutrophils, Total (Abs), Low - Grade 1 | 4 | 3 | 0 |
| Neutrophils, Total (Abs), Low - Grade 2 | 1 | 0 | 1 |
| Platelets, Low - Any Grade | 17 | 17 | 12 |
| Platelets, Low - Grade 1 | 14 | 15 | 9 |
| Platelets, Low - Grade 2 | 2 | 0 | 2 |
| Platelets, Low - Grade 3 | 1 | 1 | 0 |
| Platelets, Low - Grade 4 | 0 | 1 | 1 |
| Potassium, Low - Any Grade | 29 | 19 | 25 |
| Potassium, Low - Grade 2 | 25 | 18 | 23 |
| Potassium, Low - Grade 3 | 4 | 1 | 2 |
| Potassium, High - Any Grade | 15 | 25 | 16 |
| Potassium, High - Grade 1 | 7 | 19 | 12 |
| Potassium, High - Grade 2 | 5 | 3 | 3 |
| Potassium, High - Grade 3 | 2 | 3 | 1 |
| Potassium, High - Grade 4 | 1 | 0 | 0 |
| INR, High - Any Grade | 71 | 69 | 75 |
| INR, High - Grade 1 | 60 | 61 | 67 |
| INR, High - Grade 2 | 9 | 8 | 6 |
| INR, High - Grade 3 | 2 | 0 | 2 |
| aPTT, High - Any Grade | 47 | 42 | 42 |
| aPTT, High - Grade 1 | 38 | 35 | 36 |
| aPTT, High - Grade 2 | 6 | 5 | 3 |
| aPTT, High - Grade 3 | 3 | 2 | 3 |
| Sodium, Low - Any Grade | 67 | 58 | 58 |
| Sodium, Low - Grade 1 | 60 | 50 | 51 |
| Sodium, Low - Grade 2 | 6 | 6 | 7 |
| Sodium, Low - Grade 3 | 1 | 1 | 0 |
| Sodium, Low - Grade 4 | 0 | 1 | 0 |
| Sodium, High - Any Grade | 17 | 16 | 23 |
| Sodium, High - Grade 1 | 11 | 10 | 21 |
| Sodium, High - Grade 2 | 5 | 5 | 1 |
| Sodium, High - Grade 3 | 0 | 1 | 0 |
| Sodium, High - Grade 4 | 1 | 0 | 1 |
| Bilirubin, High - Any Grade | 16 | 14 | 11 |
| Bilirubin, High - Grade 1 | 12 | 9 | 8 |
| Bilirubin, High - Grade 2 | 2 | 5 | 2 |
| Bilirubin, High - Grade 3 | 2 | 0 | 1 |
| Uric Acid, High - Any Grade | 33 | 24 | 22 |
| Uric Acid, High - Grade 3 | 33 | 24 | 22 |
| Total Leukocyte Count, Low - Any Grade | 12 | 6 | 10 |
| Total Leukocyte Count, Low - Grade 1 | 10 | 6 | 10 |
| Total Leukocyte Count, Low - Grade 2 | 2 | 0 | 0 |
The number of participants with vital sign abnormalities outside of the normal upper (i.e., High) and lower limits (i.e., Low) were summarized for each parameter. The normal reference range used for each vital sign parameter was as follows: Diastolic Blood Pressure, 50-90 millimetres of mercury (mmHg); Oxygen Saturation, ≥94%; Pulse Rate, 60-100 beats per minute; Respiratory Rate, 8-20 breaths per minute; Systolic Blood Pressure, 90-140 mmHg; Temperature, 36.5-38 degrees Celsius (C). Not every vital sign abnormality qualified as an adverse event. A vital sign result was to be reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgement.
| Participants | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Diastolic Blood Pressure - Low | 23 | 23 | 21 |
| Diastolic Blood Pressure - High | 39 | 43 | 39 |
| Oxygen Saturation - Low | 112 | 107 | 105 |
| Pulse Rate - Low | 66 | 66 | 61 |
| Pulse Rate - High | 75 | 62 | 57 |
| Respiratory Rate - Low | 1 | 0 | 2 |
| Respiratory Rate - High | 108 | 104 | 103 |
| Systolic Blood Pressure - Low | 20 | 11 | 17 |
| Systolic Blood Pressure - High | 77 | 81 | 70 |
| Temperature - Low | 116 | 113 | 113 |
| Temperature - High | 13 | 10 | 14 |
Electrocardiogram (ECG) recordings were to be performed after the participant had been resting in a supine position for at least 10 minutes if possible. The investigator's interpretation of the ECG (e.g., normal or abnormal) was recorded.
| Participants | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| Baseline - Abnormal ECG | 56 | 60 | 55 |
| Baseline - Normal ECG | 76 | 66 | 75 |
| Day 14 - Abnormal ECG | 20 | 13 | 14 |
| Day 14 - Normal ECG | 14 | 16 | 10 |
| Day 28 - Abnormal ECG | 12 | 3 | 4 |
| Day 28 - Normal ECG | 3 | 2 | 3 |
| Discharge Day - Abnormal ECG | 27 | 28 | 37 |
| Discharge Day - Normal ECG | 37 | 47 | 39 |
| Study Completion Visit - Abnormal ECG | 13 | 18 | 21 |
| Study Completion Visit - Normal ECG | 56 | 46 | 40 |
| Study Completion Visit - Unable to Evaluate ECG | 0 | 1 | 1 |
Serum samples were collected, and participants who received treatment with MSTT1041A or MSTT1041A-matched placebo were assessed for antidrug antibodies (ADAs) to MSTT1041A, while those who received UTTR1147A or UTTR1147A-matched placebo were assessed for ADAs to UTTR1147A. Participants who received placebo treatment were only assessed for the presence of ADAs at baseline. The percentage of ADA-positive participants at baseline (baseline prevalence) and after drug administration (postbaseline incidence) are summarized. When determining postbaseline incidence, participants were considered to be ADA positive if they were ADA negative or had missing data at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more postbaseline samples was at least 0.60 titer unit greater than the titer of the baseline sample (treatment-enhanced ADA response).
| Percentage of participants | MSTT1041A-Matched Placebo | MSTT1041A | UTTR1147A-Matched Placebo | UTTR1147A |
|---|---|---|---|---|
| ADA Positive at Baseline | 3.4 | 2.6 | 1.7 | 1.6 |
| ADA Positive Post-Baseline (Total) | — | 2.9 | — | 0.9 |
| Treatment-Induced ADA Positive Post-Baseline | — | 1.9 | — | 0.9 |
| Treatment-Enhanced ADA Positive Post-Baseline | — | 1.0 | — | 0.0 |
| nanograms per millilitre (ng/mL) | UTTR1147A - PK Participants Who Only Received First Dose | UTTR1147A - PK Participants Who Received Both Doses | UTTR1147A - All PK Participants (First Dose Only or Both Doses), Days 1 to 15 |
|---|---|---|---|
| Day 1, 0.5 hours post-dose | 1260 ± 568 | 1600 ± 1820 | 1320 ± 952 |
| Day 2 | 707 ± 268 | 674 ± 372 | 700 ± 290 |
| Day 3 | 518 ± 221 | 604 ± 222 | 537 ± 223 |
| Day 7 | 258 ± 110 | 259 ± 109 | 258 ± 109 |
| Day 15, pre-dose | 42.3 ± 27.8 | 88.1 ± 40.6 | 81.8 ± 41.9 |
| Day 15, 0.5 hours post-dose | — | 1410 ± 802 | — |
| Day 21 | 2.69 ± NA | 297 ± 147 | — |
| Day 28 | 11.3 ± 8.89 | 173 ± 78.4 | — |
| micrograms per millilitre (μg/mL) | MSTT1041A - PK Participants Who Only Received First Dose | MSTT1041A - PK Participants Who Received Both Doses | MSTT1041A - All PK Participants (First Dose Only or Both Doses), Days 1 to 15 |
|---|---|---|---|
| Day 1, 0.5 hours post-dose | 206 ± 71.1 | 227 ± 66.7 | 210 ± 70.4 |
| Day 2 | 175 ± 49.1 | 178 ± 54.3 | 176 ± 50.0 |
| Day 3 | 147 ± 40.1 | 135 ± 41.0 | 144 ± 40.4 |
| Day 7 | 88.6 ± 32.3 | 83.9 ± 28.1 | 87.1 ± 30.9 |
| Day 15, pre-dose | 32.2 ± 15.2 | 33.8 ± 17.2 | 33.5 ± 16.6 |
| Day 15, 0.5 hours post-dose | — | 144 ± 48.0 | — |
| Day 21 | — | 45.4 ± 20.8 | — |
| Day 28 | — | 22.5 ± 9.17 | — |
Collected over From Baseline until study completion/discontinuation (up to 60 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Placebo | 23/134 (17.2%) | 38/134 (28.4%) | 29/134 (21.6%) |
| MSTT1041A | 23/130 (17.7%) | 38/130 (29.2%) | 42/130 (32.3%) |
| UTTR1147A | 21/132 (15.9%) | 34/132 (25.8%) | 40/132 (30.3%) |
| Event | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 5/134 | 7/130 | 5/132 |
| Cardio-respiratory arrestCardiac disorders | 5/134 | 0/130 | 1/132 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 5/134 | 2/130 | 0/132 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 5/134 | 4/130 | 2/132 |
| Septic shockInfections and infestations | 3/134 | 3/130 | 4/132 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/134 | 1/130 | 4/132 |
| Atrial fibrillationCardiac disorders | 2/134 | 3/130 | 0/132 |
| COVID-19Infections and infestations | 2/134 | 3/130 | 1/132 |
| PneumoniaInfections and infestations | 1/134 | 3/130 | 0/132 |
| Acute kidney injuryRenal and urinary disorders | 2/134 | 2/130 | 3/132 |
| Event | All Placebo | MSTT1041A | UTTR1147A |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 6/134 | 10/130 | 10/132 |
| AnaemiaBlood and lymphatic system disorders | 6/134 | 9/130 | 7/132 |
| HypokalaemiaMetabolism and nutrition disorders | 8/134 | 9/130 | 8/132 |
| Dry skinSkin and subcutaneous tissue disorders | 5/134 | 4/130 | 9/132 |
| HypertensionVascular disorders | 4/134 | 8/130 | 2/132 |
| AnxietyPsychiatric disorders | 1/134 | 5/130 | 8/132 |
| HeadacheNervous system disorders | 4/134 | 7/130 | 4/132 |
| HypotensionVascular disorders | 5/134 | 7/130 | 5/132 |
| NauseaGastrointestinal disorders | 2/134 | 3/130 | 7/132 |
Modified Intent-to-Treat (mITT) Population: all participants randomized in the study who received at least one dose of study drug, with participants grouped according to the treatment assigned at randomization.
| Age, Continuous(Years) | All Placebo | MSTT1041A | UTTR1147A | Total |
|---|---|---|---|---|
| Mean | 56.0 ± 13.5 | 57.3 ± 13.4 | 57.8 ± 12.6 | 57.0 ± 13.1 |
| Sex: Female, Male(Participants) | All Placebo | MSTT1041A | UTTR1147A | Total |
|---|---|---|---|---|
| Female | 45 | 56 | 52 | 153 |
| Male | 89 | 74 | 80 | 243 |
| Ethnicity (NIH/OMB)(Participants) | All Placebo | MSTT1041A | UTTR1147A | Total |
|---|---|---|---|---|
| Hispanic or Latino | 77 | 72 | 70 | 219 |
| Not Hispanic or Latino | 53 | 53 | 58 | 164 |
| Unknown or Not Reported | 4 | 5 | 4 | 13 |
| Race/Ethnicity, Customized(Participants) | All Placebo | MSTT1041A | UTTR1147A | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 4 | 0 | 6 |
| Asian | 6 | 4 | 5 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 4 | 1 | 5 |
| Black or African American | 10 | 7 | 10 | 27 |
| White | 92 | 87 | 89 | 268 |
| Unknown | 24 | 24 | 27 | 75 |
| Region of Enrollment(Participants) | All Placebo | MSTT1041A | UTTR1147A | Total |
|---|---|---|---|---|
| North America | 99 | 97 | 97 | 293 |
| South America | 19 | 20 | 20 | 59 |
| Western Europe | 16 | 13 | 15 | 44 |
| Country of Enrollment(Participants) | All Placebo | MSTT1041A | UTTR1147A | Total |
|---|---|---|---|---|
| Brazil | 19 | 20 | 20 | 59 |
| Mexico | 14 | 23 | 17 | 54 |
| Spain | 16 | 13 | 15 | 44 |
| United States | 85 | 74 | 80 | 239 |
| Mechanical Ventilation Required (Yes/No)(Participants) | All Placebo | MSTT1041A | UTTR1147A | Total |
|---|---|---|---|---|
| Yes, Baseline Mechanical Ventilation | 12 | 13 | 11 | 36 |
| No Baseline Mechanical Ventilation | 122 | 117 | 121 | 360 |
| Clinical Status Score at Baseline(Participants) | All Placebo | MSTT1041A | UTTR1147A | Total |
|---|---|---|---|---|
| Clinical Status Score of 1 | 0 | 0 | 0 | 0 |
| Clinical Status Score of 2 | 3 | 4 | 1 | 8 |
| Clinical Status Score of 3 | 47 | 49 | 57 | 153 |
| Clinical Status Score of 4 | 71 | 64 | 63 | 198 |
| Clinical Status Score of 5 | 10 | 8 | 8 | 26 |
| Clinical Status Score of 6 | 3 | 4 | 2 | 9 |
| Clinical Status Score of 7 | 0 | 0 | 0 | 0 |
| Clinical Status Score Not Available | 0 | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Jun 2020 to primary completion in Jan 2021, 7 months.
Results were first posted in Jan 2022, 1 year after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 7 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Astegolimab · Efmarodocokin alfa